| Mental Retardation |
2020-001878-29: Impact of a working method on traumatic memory under PROPRanolol in ADOlescents with post-traumatic stress syndrome (PROPRADO) Impact d’une méthode de travail sur la mémoire traumatique sous PROPRanolol chez des ADOlescents atteints du syndrome de stress post-traumatique (PROPRADO) |
|
|
| Not yet recruiting | 3 | 74 | Europe | chlorhydrate de propranolol, cellulose microcristalline, propranolol, placebo, Capsule | Rennes University Hospital, Hospital clinical research programme | post-traumatic stress disorder trouble du stress post-traumatique, PTSD TPST, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-004006-26: Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 years of age) with Schizophrenia |
|
|
| Ongoing | 3 | 330 | Europe | cariprazine, RGH-188, Capsule, hard | Allergan Ltd, Allergan Ltd. | Adolescent Patients (13 to 17 years of age) with Schizophrenia, Adolescent Patients (13 to 17 years of age) with Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2015-002181-23: Efficacy and safety of 2 doses of agomelatine (10mg, 25mg) given orally in children (from 7 to less than 12 years) and adolescents (from 12 to less than 18 years) with moderate to severe Major Depressive Disorder. |
|
|
| Ongoing | 3 | 484 | Europe, RoW | Agomelatine, Fluoxetine, S20098, Film-coated tablet, Oral solution, Valdoxan, Fluoxetine | Institut de Recherche International Servier, ADIR | Major Depressive Disorder, Major Depressive Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2016-000061-23: A 12-Week Extension Study looking at the effects of Lurasidone (SM-13496) in Subjects with Schizophrenia |
|
|
| Ongoing | 3 | 283 | Europe | Lurasidone, SM-13496, Film-coated tablet, Latuda | Sunovion Pharmaceuticals Inc., Sunovion Pharmaceuticals Inc. | Schizophrenia, Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2016-003437-18: A phase 3 study to Evaluate the Efficacy and Safety of Pimavanserin for the Treatment of Schizophrenia |
|
|
| Ongoing | 3 | 308 | Europe | Pimavanserin, ACP-103, Tablet | ACADIA Pharmaceuticals Inc., ACADIA Pharmaceuticals Inc. | Schizophrenia, Chronic, debilitating mental illness characterized by disturbances in thinking, emotional reaction, and behavior, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2017-003074-14: A study to evaluate Samyr effectiveness and safety profile. The study is done by comparing that Samyr injection is better than placebo injection in subjects with depression which are treated regularly with antidepressant tablet treatment. Uno studio per valutare l'efficacia e il profilo di sicurezza di Samyr. Lo studio viene effettuato confrontando che l'iniezione di Samyr ¿ migliore dell'iniezione di placebo in soggetti con depressione trattati regolarmente con il trattamento con compresse antidepressive. |
|
|
| Ongoing | 3 | 468 | Europe | SAMYR, SAMYR, Powder and solvent for solution for injection, SAMYR - 400 MG/5 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 5 FLACONCINI POLVERE + 5 FIALE SOLVENTE 5 ML | MYLAN INC., Mylan Inc. | Major Depression Disorders Disturbo Depressivo Maggiore, Major Depression Depressione maggiore, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Ongoing | 3 | 250 | RoW | LY03004, RISPERDAL® CONSTA®, TEST, REFERENCE, Powder and solvent for prolonged-release suspension for injection, EU Risperdal® Consta® | Nanjing Luye Pharmaceutical Co., Ltd., Nanjing Luye Pharmaceutical Co., Ltd., Luye Pharma Group, Ltd. | schizophrenia, schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-004460-63: Extended-release Pharmacotherapy for Opioid Use Disorder (EXPO) |
|
|
| Not yet recruiting | 3 | 600 | Europe | Sublocade, Buprenorphine, METHADONE, Buprenorphine-Naloxone, Espranor Oral lyophilisate, RBP-6000, Solution for infusion in pre-filled syringe, Sublingual tablet, Oral liquid, Oral lyophilisate, SUBOXONE, Espranor | South London and Maudsley NHS Foundation Trust, King's College London, INDIVIOR UK | Opiod addiction, Opiod Addiction, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-002640-25: A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Subjects With Major Depressive Disorder |
|
|
| Not yet recruiting | 3 | 546 | Europe | Sage-217, Capsule | Sage Therapeutics, Inc., Sage Therapeutics, Inc. | MAJOR DEPRESSIVE DISORDER, MAJOR DEPRESSIVE DISORDER, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-003251-37: A study to evaluate the safety of Pimavanserin therapy in subject with Major Depressive Disorder |
|
|
| Not yet recruiting | 3 | 280 | Europe | Pimavanserin, ACP-103, Film-coated tablet | ACADIA Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc | Major Depressive Disorder, Major Depressive Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-002749-12: Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression |
|
|
| Not yet recruiting | 3 | 514 | Europe | ITI-007, Capsule | Intra-Cellular Therapies, Inc. (ITI), Intra-Cellular Therapies, Inc. (ITI) | Major depressive episodes associated with bipolar I or bipolar II disorder (bipolar depression), Bipolar Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-002787-32: Antidepressant for the prevention of DEPression following first episode Psychosis trial |
|
|
| Not yet recruiting | 3 | 508 | Europe | Sertraline, Film-coated tablet | University of Birmingham, National Institute for Health Research | Patients with First Episode Psychosis., Patients who are experience symptoms of psychosis for the first time., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-001424-34: A study to Evaluate SAGE-217 for the Treatment of Adults with Post-Partum Depression |
|
|
| Not yet recruiting | 3 | 192 | Europe | SAGE-217, Capsule, hard | Sage Therapeutics, Inc., Sage Therapeutics, Inc. | POSTPARTUM DEPRESSION, POSTPARTUM DEPRESSION, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-003252-20: A study of the safety of pimavanserin in adult subjects with major depressive disorder |
|
|
| Not yet recruiting | 3 | 420 | Europe | Pimavanserin, ACP-103, Film-coated tablet | ACADIA Pharmaceuticals Inc, Acadia Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, Acadia Pharmaceuticals Inc | Major Depressive Disorder, Major Depressive Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-003164-31: The purpose of this study is to look into the safety and efficacy ofcariprazine as an add-on medication in the treatment of major depressivedisorder. |
|
|
| Not yet recruiting | 3 | 750 | RoW, Europe | Cariprazine, Capsule | Allergan Ltd., Allergan Sales LLC | Major Depressive Disorder, Clinical Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-001192-17: A Study to Assess the Efficacy and Safety of Lumateperone as Add on Therapy in the Treatment of Patients with Major Depressive Disorder |
|
|
| Not yet recruiting | 3 | 470 | RoW, Europe | Lumateperone, ITI-007, Capsule | Intra-Cellular Therapies, Inc., Intra-Cellular Therapies, Inc. | Major Depressive Disorder, Major Depressive Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-002068-30: Study of Lumateperone for the Prevention of Relapse in Patients with Schizophrenia |
|
|
| Not yet recruiting | 3 | 800 | Europe | Lumateperone, ITI-007, Capsule, Caplyta | Intra-Cellular Therapies, Inc., Intra-Cellular Therapies, Inc. | Schizophrenia, Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-001172-41: A Study to Assess the Safety and Tolerability of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder |
|
|
| Not yet recruiting | 3 | 760 | RoW, Europe | Lumateperone, ITI-007, Capsule, CAPLYTA | Intra-Cellular Therapies, Inc., Intra-Cellular Therapies, Inc. | Major Depressive Disorder, Major Depressive Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-001212-29: A Study to Assess the Efficacy and Safety of Lumateperone as Add on Therapy in the Treatment of Patients with Major Depressive Disorder |
|
|
| Not yet recruiting | 3 | 470 | Europe, RoW | Lumateperone, ITI-007, Capsule | Intra-Cellular Therapies, Inc., Intra-Cellular Therapies, Inc. | Major Depressive Disorder, Major Depressive Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-004532-30: A 24 month Open-Label, international study of paliperidone 6 month formulation in patients with who have completed study R092670PSY3015 Schizophrenia is a mental illness with a number of symptoms, including disorganised thinking and speech, hearing or seeing things that are not there and delusions (fixed, false beliefs). |
|
|
| Not yet recruiting | 3 | 180 | Europe | 1092mg paliperidone palmitate extended release suspension for injection (eq. 700 mg paliperidone), 1560 mg paliperidone palmitate extended release suspension for injection (eq. 1000 mg paliperidone), R092670, Prolonged-release suspension for injection in pre-filled syringe | Janssen-Cilag International NV, JANSSEN CILAG INTERNATIONAL NV, Janssen Research & Development, LLC, Janssen-Cilag SpA, Janssen-Cilag International NV | Schizophrenia, Schizophrenia, a mental illness with a number of symptoms, including disorganised thinking and speech, hearing or seeing things that are not there and delusions (fixed, false beliefs), Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-004193-64: A Study to assess the effectivenss of Brilaroxazine (RP5063) in Subjects with an Acute Exacerbation of Schizophrenia. |
|
|
| Not yet recruiting | 3 | 402 | Europe | Brilaroxazine, RP5063, Tablet | Reviva Pharmaceuticals Holdings Inc., Reviva Pharmaceuticals Holdings Inc. | Acute Exacerbation of Schizophrenia, Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-003714-39: Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia |
|
|
| Not yet recruiting | 3 | 400 | Europe | Valbenazine, NBI-98854, Capsule | Neurocrine Biosciences, Inc., Neurocrine Biosciences, Inc. | Schizophrenia, Schizophrenia, Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04] | | | | |
2021-003850-21: Treating depression with anti-inflammatory drugs Behandeling van depressie met ontstekingsremmers |
|
|
| Ongoing | 3 | 140 | Europe | Celecoxib, Capsule, hard, Celecoxib | Amsterdam UMC, location VUmc, Amsterdam UMC, location VUmc, Hersenstichting | Immuno metabolic Depression Immuno metabole depressie, Depression with imflammation and energy-related symptoms Depressie met onstekingen en energie-gerelateerde symptomen, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-001515-10: A Phase 3 study to assess the safety of KarXT and how it helps in reoccurrence prevention in people with psychosis associated with Alzheimer’s Disease Dementia as compared to placebo Un estudio de fase 3 para evaluar la seguridad de KarXT y cómo ayuda aprevenir la recurrencia en personas con psicosis asociada con la demenciapor enfermedad de Alzheimer en comparación con un placebo |
|
|
| Not yet recruiting | 3 | 380 | Europe, RoW | KarXT, [--], [n/a], Capsule, hard | Karuna Therapeutics, Karuna Therapeutics, Inc., Karuna Therapeutics, Karuna Therapeutics, Inc. | Psychosis Associated with Alzheimer’s Disease Dementia Psicosis asociada con la demencia de la enfermedad de Alzheimer, Delusions or hallucinations associated with mild to severe Alzheimer’s disease memory loss Delirios o alucinaciones asociados con la pérdida de memoria leve agrave de la enfermedad de Alzheimer, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-001666-35: A rollover study for subjects that complete Kar-012, to assess Long-term Safety and Tolerability of KarXT in combination with specified atypical antipsychotics in Subjects with Inadequately Controlled Symptoms of Schizophrenia |
|
|
| Not yet recruiting | 3 | 280 | Europe | KarXT, Capsule, hard | Karuna Therapeutics, Inc., Karuna Therapeutics, Inc. | Schizophrenia, Brain disorder that causes altered state that affects a person's ability to think, feel, and behave clearly., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-001665-12: A Phase 3 study to assess the safety and effectiveness of KarXT in combination with specific approved atypical antipsychotic medications to reduce the signs and symptoms of Schizophrenia in adult subjects. |
|
|
| Not yet recruiting | 3 | 400 | Europe | KarXT, Capsule, hard | Karuna Therapeutics, Inc., Karuna Therapeutics, Inc. | Schizophrenia, brain disorder that causes altered state of affect a person's ability to think, feel, and behave clearly., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-000430-42: a study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression. |
|
|
| Ongoing | 3 | 840 | Europe, RoW | Aticaprant, JNJ-67953964, Tablet | Janssen-Cilag International NV, Janssen Research & Development, LLC | Major Depressive Disorder (MDD) Major depressziós zavar (MDD), Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-000461-41: A study to evaluate the effectiveness of aticaprant as an add on treatment in patients with depression who have not responded sufficiently to their current antidepressant. |
|
|
| Not yet recruiting | 3 | 538 | RoW, Europe | Aticaprant, JNJ-67953964, Tablet | Janssen-Cilag International NV, Janssen Research & Development, LLC | Major Depressive Disorder (MDD), Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2017-003073-33: A research study to compare the antidepressant ability and safety of Samyr® tablets versus placebo tablets as an adjunct to additional antidepressant treatment in patients with major depressive disorder (MDD) Uno studio di ricerca per confrontare l'abilità antidepressiva e la sicurezza delle compresse di Samyr® rispetto alle compresse di placebo in aggiunta al trattamento con antidepressivi aggiuntivo nei pazienti con disturbo di depressione maggiore (MDD) |
|
|
| Not yet recruiting | 3 | 600 | Europe | Samyr, [NA], Gastro-resistant tablet, SAMYR - 400 MG COMPRESSE GASTRORESISTENTI20 COMPRESSE | Mylan Inc., Mylan Inc. | Major Depression Disorder Disturbo Depressivo Maggiore, Major Depression Depressione maggiore, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-001865-11: A Study to Test if TV-44749 is Effective in Relieving Schizophrenia |
|
|
| Not yet recruiting | 3 | 640 | Europe | Olanzapine, TV44749, Powder and solvent for prolonged-release suspension for injection | Teva Branded Pharmaceutical Products R&D, Inc., Teva Branded Pharmaceutical Products R&D, Inc. | Schizophrenia is a serious mental disorder in which people interpret reality abnormally. It is a severely debilitating psychotic disorder characterized by positive symptoms (eg, delusions, hallucinations, and grossly disorganized behavior) and negative symptoms (eg, affective flattening, alogia, and avolition)., Schizophrenia is a mental disorder that may result in some combination of hallucinations, delusions, and extremely disordered thinking and behavior that impairs daily functioning and can be disabling, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-000439-22: A study to evaluate the effectiveness of aticaprant as an add on treatment in patients with depression who have not responded sufficiently to their current antidepressant. |
|
|
| Ongoing | 3 | 538 | Europe, RoW | Aticaprant, JNJ-67953964, Tablet | Janssen-Cilag International NV, Janssen Research & Development, LLC | Major Depressive Disorder (MDD), Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-000688-22: A phase III study evaluating the efficacy and safety of Silexan in patients with mild to moderate depression Eine Phase 3 Studie zum Nachweis der Wirksamkeit und Sicherheit von Silexan bei Patienten mit einer leichten bis mittelschweren Depression |
|
|
| Not yet recruiting | 3 | 498 | Europe | Silexan, sertralin-biomo 50 mg Filmtabletten, WS® 1265, Capsule, soft, Tablet, Lasea®, Sertralin-biomo 50 mg Filmtabletten | Dr. Willmar Schwabe GmbH & Co. KG, Dr. Willmar Schwabe GmbH & Co. KG | Major Depressive Disorder Akute Episode einer depressiven Erkrankung, Depression Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-000405-83: A clinical study to evaluate iloperidone in the treatment of patients with acute manic episodes associated with Bipolar I Disorder Badanie kliniczne oceniające stosowanie iloperidonu w leczeniu pacjentów z ostrymi epizodami manii związanymi z chorobą dwubiegunową typu I |
|
|
| Not yet recruiting | 3 | 400 | Europe, RoW | Iloperidone, VYV-683, Capsule, Tablet | Vanda Pharmaceuticals Inc., Vanda Pharmaceuticals Inc. | Acute manic episodes associated with Bipolar I Disorder Ostre epizody manii związane z chorobą dwubiegunową typu I, Bipolar I Disorder Choroba dwubiegunowa typu I, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Recruiting | 3 | 800 | Europe, US | Donanemab, LY3002813, Placebo | Eli Lilly and Company | Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 06/24 | 05/25 | | |
2018-004899-35: Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148 |
|
|
| Not yet recruiting | 3 | 95 | US | Rexulti, Tablet, Rexulti | Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | Irritability Associated With Autism Spectrum Disorder, AutismAutism Spectrum DisorderASDIrritability, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2019-000723-40: Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder ( Anchor ) |
|
|
| Not yet recruiting | 3 | 130 | US | Rexulti, Tablet, Rexulti | Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | Irritability Associated With Autism Spectrum Disorder (ASD), AutismIrritabilityAutism Spectrum DisorderASD, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
2017-001169-26: Evaluation of NaBen® (sodium benzoate) in treatment of schizophrenia in adults |
|
|
| Not yet recruiting | 2/3 | 348 | Europe | NaBen®(F.C.T.II), NaBen®(F.C.T.II), Film-coated tablet | SyneuRx International (Taiwan) Corp, SyneuRx International (Taiwan) Corp. | Treatment for Schizophrenia in Adults, Treatment for Schizophrenia in Adults, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2017-001170-42: Two-part Clinical Study to Evaluate the Safety and Efficacy of NaBen® in Adults with Refractory Schizophrenia |
|
|
| Not yet recruiting | 2/3 | 287 | Europe, RoW | NaBen®(F.C.T.II), NaBen®(F.C.T.II), Film-coated tablet | SyneuRx International (Taiwan) Corp, SyneuRx International (Taiwan) Corp | Treatment for Refractory Schizophrenia in Adults, Treatment for treatment-resistant Schizophrenia in Adults, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-006062-36: A Phase II/III, randomized, 4-week, placebo-controlled study, designed to determine the safety, tolerability, and efficacy of evenamide (NW-3509) in patients with chronic schizophrenia. |
|
|
| Ongoing | 2/3 | 196 | Europe, RoW | Evenamide, NW3509, Capsule, hard | Newron Pharmaceuticals S.p.A., NEWRON PHARMACEUTICALS SPA, Newron Pharmaceuticals S.p.A, Newron Pharmaceuticals S.p.A., Newron Pharmaceuticals S.p.A | Chronic schizophrenia, Chronic schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-002093-34: Phase II / III, open-label, extension study designed to determine the long-term safety, tolerability and efficacy of evenamide (NW-3509) in patients with psychiatric disorders who participated in previous trials with evenamide. Studio di fase II/III, di estensione, in aperto, progettato per determinare la sicurezza a lungo termine, la tollerabilità e l'efficacia di evenamide (NW-3509) in pazienti con disturbi psichiatrici che hanno partecipato a precedenti studi con evenamide. |
|
|
| Not yet recruiting | 2/3 | 500 | Europe | Evenamide, [NW3509], Capsule, hard | NEWRON PHARMACEUTICALS SPA, Newron Pharmaceuticals S.p.A | Patients with psychiatric disorders who participated in a previous trial with evenamide. Pazienti con disturbi psichiatrici che hanno partecipato a una precedente sperimentazione con evenamide., Patients with psychiatric disorders who participated in a previous trial with evenamide. Pazienti con disturbi psichiatrici che hanno partecipato a una precedente sperimentazione con evenamide., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-001352-33: A clinical trial to assess the efficacy, safety, and tolerability of AVP-786 versus placebo for the treatment of negative symptoms of schizophrenia |
|
|
| Not yet recruiting | 2/3 | 370 | Europe | Deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q], AVP-786, Capsule, hard | Otsuka Pharmaceutical Development & Commercialization, Inc., Avanir Pharmaceuticals, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc, Avanir Pharmaceuticals, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | Negative symptoms of schizophrenia, Negative symptoms of schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
